BackIGM Biosciences Overview

IGM Biosciences Total Current Liabilities

Latest total current liabilities for IGMS: $6.1M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$6.06M
↓ 83.91% YoYΔ $-31.59M vs prior year quarter

Peer trimmed avg / median

Loading

IGM Biosciences Total Current Liabilities History

Loading

IGM Biosciences vs. peers: Total Current Liabilities Comparison

Loading

IGM Biosciences Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

IGM Biosciences (IGMS) FAQ

IGM Biosciences (IGMS) currently reports a total current liabilities of $6.1M as of June 2025. That compares with $38M in the prior-year period — down 83.9% year over year. Use the charts on this page to explore IGM Biosciences's total current liabilities history and peer comparisons.

IGM Biosciences's total current liabilities decreased from $38M to $6.1M — a 83.9% year-over-year decrease (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

IGM Biosciences reported $6.1M in total current liabilities as of June 2025. That compares with $38M in the prior-year period — down 83.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $6.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for IGM Biosciences, and consider following IGMS for alerts when major investors trade the stock.

IGM Biosciences is classified in the Healthcare sector. On total current liabilities, it currently shows $6.1M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IGMS with unrelated industries.